Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sutro Biopharma (STRO) Cash from Operations (2017 - 2025)

Historic Cash from Operations for Sutro Biopharma (STRO) over the last 9 years, with Q3 2025 value amounting to -$38.2 million.

  • Sutro Biopharma's Cash from Operations rose 4080.69% to -$38.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$222.5 million, marking a year-over-year decrease of 11047.38%. This contributed to the annual value of -$191.5 million for FY2024, which is 7160.62% down from last year.
  • Latest data reveals that Sutro Biopharma reported Cash from Operations of -$38.2 million as of Q3 2025, which was up 4080.69% from -$44.7 million recorded in Q2 2025.
  • Sutro Biopharma's Cash from Operations' 5-year high stood at $65.9 million during Q3 2022, with a 5-year trough of -$71.7 million in Q4 2024.
  • Moreover, its 5-year median value for Cash from Operations was -$31.2 million (2023), whereas its average is -$28.0 million.
  • Per our database at Business Quant, Sutro Biopharma's Cash from Operations soared by 36982.71% in 2022 and then tumbled by 87912.74% in 2023.
  • Sutro Biopharma's Cash from Operations (Quarter) stood at -$21.6 million in 2021, then dropped by 10.58% to -$23.9 million in 2022, then surged by 158.97% to $14.1 million in 2023, then crashed by 609.79% to -$71.7 million in 2024, then surged by 46.77% to -$38.2 million in 2025.
  • Its Cash from Operations stands at -$38.2 million for Q3 2025, versus -$44.7 million for Q2 2025 and -$67.9 million for Q1 2025.